KURA ONCOLOGY INC(NASDAQ:KURA) stock Fundamental Analysis

Fundamental Rating

Overall KURA gets a fundamental rating of 2 out of 10. We evaluated KURA against 572 industry peers in the Biotechnology industry. While KURA seems to be doing ok healthwise, there are quite some concerns on its profitability. KURA is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

KURA had negative earnings in the past year.

KURA had a negative operating cash flow in the past year.

KURA had negative earnings in each of the past 5 years.

KURA had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

KURA has a Return On Assets (-41.26%) which is in line with its industry peers.

KURA's Return On Equity of -46.62% is fine compared to the rest of the industry. KURA outperforms 68.32% of its industry peers.

		Industry Rank	Sector Rank
ROA	-41.26%
ROE	-46.62%
ROIC	N/A

ROA(3y)-29.4%

ROA(5y)-25.63%

ROE(3y)-32.16%

ROE(5y)-28%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KURA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

The number of shares outstanding for KURA has been increased compared to 1 year ago.

The number of shares outstanding for KURA has been increased compared to 5 years ago.

The debt/assets ratio for KURA is higher compared to a year ago.

2.2 Solvency

KURA has an Altman-Z score of 3.58. This indicates that KURA is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of KURA (3.58) is better than 77.17% of its industry peers.

A Debt/Equity ratio of 0.02 indicates that KURA is not too dependend on debt financing.

With a Debt to Equity ratio value of 0.02, KURA perfoms like the industry average, outperforming 41.59% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Altman-Z	3.58

ROIC/WACCN/A

WACCN/A

2.3 Liquidity

A Current Ratio of 11.47 indicates that KURA has no problem at all paying its short term obligations.

The Current ratio of KURA (11.47) is better than 84.07% of its industry peers.

A Quick Ratio of 11.47 indicates that KURA has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 11.47, KURA belongs to the top of the industry, outperforming 84.07% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	11.47
Quick Ratio	11.47

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

KURA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.83%.

EPS 1Y (TTM)-16.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-26%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

KURA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.91% yearly.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y-1.5%

EPS Next 2Y-5.95%

EPS Next 3Y-3.23%

EPS Next 5Y13.91%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KURA. In the last year negative earnings were reported.

Also next year KURA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as KURA's earnings are expected to decrease with -3.23% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-5.95%

EPS Next 3Y-3.23%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for KURA!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KURA ONCOLOGY INC

NASDAQ:KURA (1/29/2025, 6:20:57 PM)

After market: 7.69 0 (0%)

7.69

-0.08 (-1.03%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-07 2024-11-07/amc

Earnings (Next)02-20 2025-02-20/amc

Inst Owners105.16%

Inst Owner Change0.02%

Ins Owners1.07%

Ins Owner Change-0.01%

Market Cap597.97M

Analysts83.64

Price Target29.14 (278.93%)

Short Float %13.9%

Short Ratio5.21

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)4.66%

Min EPS beat(2)1.27%

Max EPS beat(2)8.05%

EPS beat(4)3

Avg EPS beat(4)1.48%

Min EPS beat(4)-5.24%

Max EPS beat(4)8.05%

EPS beat(8)7

Avg EPS beat(8)6.01%

EPS beat(12)11

Avg EPS beat(12)6.1%

EPS beat(16)13

Avg EPS beat(16)4.65%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-4.23%

EPS NQ rev (1m)0%

EPS NQ rev (3m)42.93%

EPS NY rev (1m)0%

EPS NY rev (3m)15.04%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.41
P/tB	1.41
EV/EBITDA	N/A

EPS(TTM)-2.36

EYN/A

EPS(NY)-2.34

Fwd EYN/A

FCF(TTM)-2.18

FCFYN/A

OCF(TTM)-2.17

OCFYN/A

SpS0

BVpS5.45

TBVpS5.45

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-41.26%
ROE	-46.62%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-29.4%

ROA(5y)-25.63%

ROE(3y)-32.16%

ROE(5y)-28%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score4

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.02
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	13.83%
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	11.47
Quick Ratio	11.47
Altman-Z	3.58

F-Score4

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)102.68%

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)-16.83%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-26%

EPS Next Y-1.5%

EPS Next 2Y-5.95%

EPS Next 3Y-3.23%

EPS Next 5Y13.91%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-41.05%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-43.33%

EBIT Next 3Y-18.94%

EBIT Next 5Y-2.67%

FCF growth 1Y-57.28%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-58.22%

OCF growth 3YN/A

OCF growth 5YN/A

KURA ONCOLOGY INC (KURA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens